Company: DVAX
Filing Date: 2025-04-07
Form Type: PREC14A
Source: 0001193125-25-074629
Chunk: 14

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-07
Form: PREC14A
Chunk 14
---
 knowledge and experience in healthcare and pharmaceuticals. Mr. Mullette would bring to the Company strong leadership and day-to- day operational experience,
and a deep understanding of business risks, based on his leadership positions in the healthcare and biotechnology space.

Donald Santel, age 64.

Donald Santel currently serves as chairman of the board of a private biotechnology company, Tentarix Biotherapeutics, since March
2022, as an independent director of private biotechnology company, Inograft

15

Biotherapeutics, since December 2023 and independent director of private biotechnology company March Therapeutics since August 2024. Since January 2023, he has served on the board of Aerovate
Therapeutics, a public biotechnology company (NASDAQ: AVTE). He previously served as Chief Executive Officer of Hyperion Therapeutics (Nasdaq GM: HPTX) from June 2008 until the sale of the company to Horizon Pharma (Nasdaq: HZNP) for
$1.1 billion in May 2015. Previously, Mr. Santel was the Chief Executive Officer of CoTherix, Inc., (Nasdaq: CTRX) from January 2000 through its sale to Actelion for $419 million in January 2007. Prior to joining CoTherix,
Mr. Santel was employed by several medical device companies, including Cardiac Pathways Corporation (acquired by Boston Scientific) and Medtronic, Inc. Mr. Santel holds an M.S. in electrical engineering from the University of Minnesota and
a B.S.E. in biomedical engineering from Purdue University.

Mr. Santel’s many years working in the life sciences industry,
particularly as the chief executive during the sale of two such companies, provides managerial and operational perspective to the Board. Mr. Santel’s extensive experience as a healthcare chief executive officer and director would bring to
the Company strong leadership and human capital management skills, including experience managing significant mergers and acquisitions activity.

Other than as stated herein, there are no arrangements or understandings among the Deep Track Parties or any other person or persons pursuant
to which the nomination of the Deep Track Nominees described herein is to be made, other than the consent by each of the Deep Track Nominees to be named as a nominee of Deep Track Capital in any proxy statement relating to the 2025 Annual Meeting
and serving as a director of the Company if elected as such at the 2025